Evidence map›Paper›PMID 35850290›Full record

ReviewKidney international2022

HIV at 40: kidney disease in HIV treatment, prevention, and cure.

Anika Lucas, Christina M Wyatt

Open access · greenAbstract readReview
In one paragraph

Review in Kidney international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Renal Alterations Secondary to Visceral Leishmaniasis: A Scoping Review.Revista da Sociedade Brasileira de Medicina Tropical · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anika LucasDepartment of Medicine, Division of Nephrology, Duke University School of Medicine, Durham, North Carolina, USA.
Christina M WyattDepartment of Medicine, Division of Nephrology, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: christina.wyatt@duke.edu.
Duke University · US

Funding

VIRAL PATHOGENESIS OF HIV ASSOCIATED NEPHROPATHYP01DK056492 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI KLOTMAN, MARY E. · 1999 to 2021
$27.8M
Mount Sinai Nephrology Research Training GrantT32DK007757 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI CAMPBELL, KIRK N, HE, JOHN CIJIANG · 1998 to 2022
$3.8M
Impact of early antiretroviral therapy on kidney disease outcomesR01DK112258 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WYATT, CHRISTINA M · 2017 to 2021
$2.1M
NIDDK NIH HHS P01 DK056492NIDDK NIH HHS R01 DK112258NIDDK NIH HHS T32 DK007757
6 · The paper itself

Abstract

Four decades after the first cases of HIV were reported, kidney disease remains an important comorbidity in people with HIV (PWH). Both HIV-associated nephropathy and immune complex kidney disease were recognized as complications of HIV infection in the early years before treatment was available. Although the introduction of effective antiretroviral therapy in the late 1990s resulted in dramatic improvements in survival and health in PWH, several commonly used antiretroviral agents have been associated with kidney injury. HIV infection and treatment may also promote the progression of comorbid chronic kidney disease due to traditional risk factors such as diabetes, and HIV is one of the strongest "second hits" for the high-risk APOL1 genotype. Unique considerations in the management of chronic kidney disease in PWH are largely related to the need for lifelong antiretroviral therapy, with potential for toxicity, drug-drug interactions, and polypharmacy. PWH who develop progressive chronic kidney disease are candidates for all modalities of kidney replacement therapy, including kidney transplantation, and at some centers, PWH may be candidates to serve as donors for recipients with HIV. Transplantation of kidney allografts from donors with HIV also offers a unique opportunity to study viral dynamics in the kidney, with implications for kidney health and for research toward HIV cure. In addition, HIV-transgenic animal models have provided important insights into kidney disease pathogenesis beyond HIV, and experience with HIV and HIV-related kidney disease has provided important lessons for future pandemics.

Indexed as

AIDS-Associated NephropathyHIV InfectionsRenal Insufficiency, ChronicAnimalsAntigen-Antibody ComplexAnti-Retroviral AgentsApolipoprotein L1HumansAntigen-Antibody ComplexAnti-Retroviral AgentsAPOL1 protein, humanApolipoprotein L1antiretroviral nephrotoxicityAPOL1HIV-associated nephropathy

Identifiers

PMID35850290
PMCPMC9509437
OpenAlexW4285603104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.